|Hsp90 Inhibitor SNX-5422 Mesylate (Code C91068)|
|Terms & Properties|
Preferred Name: Hsp90 Inhibitor SNX-5422 Mesylate
Definition: The orally bioavailable mesylate salt of a synthetic prodrug targeting the human heat-shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX-5422 is rapidly converted to SNX-2112, which accumulates more readily in tumors relative to normal tissues. SNX-2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2/ERBB2, and the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as HER2/ERBB2, AKT, RAF1, BCR-ABL, and mutated p53, as well as many other molecules that are important in cell cycle regulation or immune responses.
NCI-GLOSS Definition: A substance being studied in the treatment of cancer. SNX-5422 mesylate blocks a protein needed for cells to grow and may kill cancer cells. It is a type of heat shock protein 90 inhibitor.
Display Name: Hsp90 Inhibitor SNX-5422 Mesylate
Label: Hsp90 Inhibitor SNX-5422 Mesylate
NCI Metathesaurus Link: C2984011 (see NCI Metathesaurus info)
Synonyms & Abbreviations: (see Synonym Details)
|Hsp90 Inhibitor SNX-5422 Mesylate|
External Source Codes:
|PDQ Closed Trial Search ID||590712|
|PDQ Open Trial Search ID||590712 (check for NCI PDQ open clinical trial info)|
|Name||Value (qualifiers indented underneath)|
Additional Concept Data:
|Defined Fully by Roles: No|